Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBOC: Rifaximin Prophylaxis for SBP in Decompensated Cirrhosis
NCT04775329Phase 3Terminated
- Sponsor
- Changi General Hospital
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in spontaneous bacterial peritonitis (SBP), sponsored by Changi General Hospital. Started Nov 2020; status: terminated.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT04775329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775329.